SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Yu Peng, Zheng Li, Shiheng Zhang, Yanli Xiong, Yanping Cun, Chengyuan Qian, Mengxia Li, Tao Ren, Lei Xia, Yi Cheng, Dong Wang, Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients, International Journal of Cancer, 2014, 135, 6
  2. 2
    John R. Davies, Rosalyn Jewell, Paul Affleck, Gabriella M. Anic, Juliette Randerson-Moor, Aija Ozola, Kathleen M. Egan, Faye Elliott, Zaida García-Casado, Johan Hansson, Mark Harland, Veronica Höiom, Guan Jian, Göran Jönsson, Rajiv Kumar, Eduardo Nagore, Judith Wendt, Håkan Olsson, Jong Y. Park, Poulam Patel, Dace Pjanova, Susana Puig, Dirk Schadendorf, P. Sivaramakrishna Rachakonda, Helen Snowden, Alexander J. Stratigos, Dimitrios Bafaloukos, Zighereda Ogbah, Antje Sucker, Joost J. den Oord, Remco Doorn, Christy Walker, Ichiro Okamoto, Pascal Wolter, Jennifer H. Barrett, D. Timothy Bishop, Julia Newton-Bishop, Inherited variation in the PARP1 gene and survival from melanoma, International Journal of Cancer, 2014, 135, 6
  3. 3
    Yanlong Yang, Lei Xian, The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis, Tumor Biology, 2014, 35, 4, 2905

    CrossRef

  4. 4
    Yanlong Yang, Lei Xian, The association between the GSTP1 A313G and GSTM1 null/present polymorphisms and the treatment response of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients: a meta-analysis, Tumor Biology, 2014,

    CrossRef

  5. 5
    Tong-Peng Xu, Hua Shen, Ling-Xiang Liu, Yong-Qian Shu, Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: A pooled analysis based on 39 reports, Gene, 2013, 526, 2, 265

    CrossRef

  6. 6
    Georgios Ioannidis, John Souglakos, Vassilis Georgoulias, Predicting toxicity in advanced lung cancer patients treated with platinum-based chemotherapy, Lung Cancer Management, 2013, 2, 4, 281

    CrossRef

  7. 7
    Nina Erčulj, Viljem Kovač, Julija Hmeljak, Alenka Franko, Metoda Dodič-Fikfak, Vita Dolžan, DNA Repair Polymorphisms and Treatment Outcomes of Patients with Malignant Mesothelioma Treated with Gemcitabine-Platinum Combination Chemotherapy, Journal of Thoracic Oncology, 2012, 7, 10, 1609

    CrossRef

  8. 8
    Elisa Giovannetti, Francesca Toffalorio, Tommaso De Pas, Godefridus J Peters, Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?, Pharmacogenomics, 2012, 13, 9, 1073

    CrossRef

  9. 9
    Hong-Gang Ke, Jun Li, Yi Shen, Qing-Sheng You, Yu Yan, Han-Xuan Dong, Jun-Hua Liu, Zhen-Ya Shen, Prognostic Significance of GSTP1, XRCC1 and XRCC3 Polymorphisms in Non-small Cell Lung Cancer Patients, Asian Pacific Journal of Cancer Prevention, 2012, 13, 9, 4413

    CrossRef

  10. 10
    Jian Chen, Qing-wei Zhao, Gen-ming Shi, Lin-run Wang, XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies, Journal of Zhejiang University SCIENCE B, 2012, 13, 11, 875

    CrossRef